Healthcare firm, Merck & Co. Inc. (MRK), Thursday said that it has been awarded a significant portion of the UNICEF human papillomavirus or HPV vaccine tender, and will provide sustained supply of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to GAVI-eligible countries.
Through this initial tender award, Merck expects to supply approximately 2.4 million doses of GARDASIL to GAVI-eligible countries between 2013 to 2017 to help meet vaccine demand for countries already approved or recommended for approval by GAVI for HPV vaccine demonstration projects and national introductions.
GARDASIL is a ready-to-use, three-dose, intramuscular vaccine.
For comments and feedback: editorial@rttnews.com